Drug intelligence / Profile preview

Kalomin

Development stage: Phase 3
Lead developer: Korea United Pharm
Administration: Oral

Overview

Kalomin is a pharmaceutical drug developed by Korea United Pharm. Inc. for the treatment of acute bronchitis. Its active ingredient is Pelargonium sidoides, a herbal extract known for its broad-spectrum activity against acute respiratory tract infections. It is currently undergoing a Phase 3 clinical trial to evaluate its efficacy and safety in patients with acute bronchitis.

Brand names: Kalomin

Beyond the preview

Go deeper on Kalomin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kalomin.

Explore the full profile